Huadong Medicine Company

Chongqing Yuyan is a biomedical innovation and medical beauty product research and development company. It intends to address the biosafety concerns associated with extracting natural botulinum toxin from the host Clostridium botulinum.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Ashvattha Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapeutics that address unmet medical needs in neurology, oncology, ophthalmology, and inflammation. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These products are designed to selectively target and treat diseases by engaging actively endocytosing cells such as reactive microglia and macrophages, which play a critical role in chronic inflammation and disease progression. By utilizing this precision targeting approach, Ashvattha Therapeutics aims to minimize off-target toxicity, systemic side effects, and immunogenicity often associated with conventional treatments, thereby enhancing treatment efficacy and patient outcomes. The company has a robust pipeline containing nine therapeutics across its areas of focus.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

Ningbo Donghai Bank offers services for business banking. They collaborate with the corporate culture of implementing sunshine management, forming a sunshine team and business, offering a sunshine service, and creating a sunny brand. They aim to create a business with qualities, values, and compassion a regional bank an enhanced service provider; to make appropriate contributions to the high-quality development of the regional economy and society, and to continuously embark on new endeavors.